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Abstract
Background Coronavirus infection is a novel respiratory disease affecting people across the world. Although the majority of
patients present with fever, dyspnea, cough, or myalgia, various signs and symptoms have been reported for this disease.
Recently, neurological symptoms have been noticed in patients with COVID-19 with unknown etiology. However, the occur-
rence of strokes in young and middle aged patients with COVID-19 is not fully explained.
Methods In this series, six patients younger than 55 years of age with diagnosis of stroke and a confirmed diagnosis of COVID-
19 were evaluated for symptoms, lab data, imaging findings, and outcomes from March 2020 to the end of April 2020 from all
stroke cases in a tertiary academic hospital. Patients older than 55 and all others who had evidence of cardiac abnormalities
(arrhythmia/valvular) were excluded.
Results Fever, myalgia, cough, and dyspnea were the most common clinical symptoms noted in 66.66% (4/6), 66.66% (4/6),
50% (3/6), and 50% (3/6) of the patients, respectively. Themean ± standard deviation (SD) of National Institutes of Health Stroke
Scale (NIHSS) for the patient was 10.16 ± 7.13 (ranged 5–24). The most involved area was middle cerebral artery (MCA) (five in
MCA versus one in basal ganglia) and the majority of our patients had a low lung involvement score (mean ± SD: 13.16 ± 6.49
out of 24). Finally, one patient was deceased and rest discharged.
Conclusion Stroke may be unrelated to age and the extent of lung involvement. However, different factors may play roles in co-
occurrence of stroke and COVID-19 and its outcome. Future studies with long-term follow-up and more cases are needed to
assess prognostic factors.
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Background
Coronavirus infection is a novel, highly contagious respiratory
disease caused by SARS-CoV-2 affecting people across the
world [1]. The most frequent symptoms are fever, dyspnea,
cough, or myalgia [2]. Although various signs and symptoms
have been reported for this disease, some of them are not clear
yet. It may involve both the central nervous system (CNS) and
peripheral nervous system (PNS). In this regard, headache, ver-
tigo, cognitive impairment, epilepsy, acute cerebrovascular event
ataxia, ageusia, anosmia, neuralgia, andGuillain-Barre syndrome
are some of the reported neurological manifestations [3–5].
According to previous reports, viral infections including
COVID-19 may play a role as a potential risk factor in devel-
oping cerebrovascular diseases such as acute ischemic stroke
especially in patients with the severe form of infection [6].
The role of COVID-19 in initiating proinflammatory and
hypercoagulable state has been well described [7]. Also, be-
cause of inflammation, hypoxia, immobilization, and diffuse
intravascular coagulation (DIC), patients with COVID-19 are
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at a higher risk of both venous and arterial thromboembolic
events. Recently, heparin has been associated with lower mor-
tality in severe cases of COVID-19 or with elevated D-dimer
[8]. However, the mechanism and its pathology are rarely
understood.
There are currently limited data about patient’s characteristics,
extent of lung involvement, and other factors in the patients with
stroke and COVID-19. This series is presented to point out to
physicians to keep cerebrovascular attacks in mind as an
important condition in patients with COVID-19 that may need
urgent interventions. In addition, the other aim of this study was
to show coronavirus as a causative agent for stroke which is
unrelated to age and lung involvement extension.
Cases
Our cases were patients presented to our academic tertiary
hospital, stroke unit, with clinical symptoms of stroke from
Table 2 Summary of baseline




8000 5500 8700 7400 4500 9000 7183.33 ± 1808.22
Neutrophil count 5600 4700 6960 6364 2925 7650 5699.83 ± 1705.38
Lymphocyte count 2400 800 1392 888 1575 1350 1400.83 ± 575.38
Hemoglobin
(mg/dL)
9.8 10.7 11.8 16.8 15.8 12.5 12.89 ± 2.80
Platelet × 103 305 183 146 223 101 210 194.66 ± 69.98
CRP (mg/L) 24 12 27 5 12 10 15.0 ± 8.57
LDH (μ/L) 345 347 1393 356 430 460 555.16 ± 413.24
Cr (mg/dL) 0.8 0.8 1.09 1.2 1.2 1.04 1.02 ± 0.18
AST (μ/L) 16 14 94 21 17 11 28.83 ± 32.09
ALT (μ/L) 15 11 106 13 10 14 28.16 ± 38.17
ALP (μ/L) 143 134 415 209 204 162 211.16 ± 104.52
Albumin (g/dL) 5.01 4.8 3.9 4.8 4.1 4.3 4.48 ± 0.44
D-Dimer 728 810 954 682 600 1293 844.50 ± 250.63
PT (s) 13 13 13 14 13 14 13.33 ± 0.51
PTT (s) 28 40 30 40 38 30 34.33 ± 5.57
INR 1 1 1 1.1 1 1.1 1.03 ± 0.51
CRP C-reactive protein, LDH lactic acid dehydrogenase, Cr creatinine, BUN blood urea nitrogen, AST aspartate
transaminase, ALT alanine transaminase, ALP alkaline phosphatase, PT prothrombin time, PTT partial thrombo-
plastin time, INR international normalized ratio














1 33/F − + lethargy Reduced level of consciousness,
global aphasia, right side
hemiplegia
85 24 5 Death




Left side hemiparesis, homonymous
hemianopia, sensory deficit,
dysarthria
89 9 10 Discharged
3 49/F HTN − Myalgia Left side hemiplagia,heminimous
hemianopia, dysarthera
90 11 14 Discharged
4 40/M − − Myalgia,
dyspnea
Right side hemiparesis, dysarthera 89 6 7 Discharged
5 53/M HTN + Cough, diarrhea Left side hemiparesis, dysarthria 91 5 7 Discharged
6 47/ F DM/HTN + Myalgia, cough
and dyspnea
Right side hemiparesis, dysarthria 82 6 9 Discharged
F female, M male, HTN hypertension, NIHHS National Institutes of Health Stroke Scale
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March 2020 to the end of April 2020. We exclude patients
older than 55 and all others who had evidence of cardiac
arrhythmia or cardiac valvular disease based on electrocardio-
gram, transthoracic and transesophageal echocardiography,
and 24-h Holter monitoring findings. Although all patients
primarily presented with neurological symptoms, the diagno-
sis of COVID-19 was made based on positive nasopharyngeal
polymerase chain reaction (PCR) and lung CT scan except
one of them who was a 49-year-old female with previous
diagnosis of COVID-19 who was discharged from another
hospital and admitted to our stroke unit 5 days later.
The mean age (±standard deviation [SD]) was 43.5 ± 7.42
(range 33–53 years) and half of them were male. COVID-19
symptoms were evaluated by history taking except one of our
cases (33 years old female) who presented altered levels of
consciousness and fever. The most common sign and symp-
tom of COVID-19 were fever (four/six), myalgia (four/six),
cough (three/six), and dyspnea (three/six). All patients had O2
saturation below 92% in room air while none of them were
hypotensive. Half of the patients had history of hypertension
and one case had diabetes mellitus.
Fig. 1 Thirty-three-year-old
female with fever and reduced
level of consciuosness who had a
history of exposure to known case
of COVID-19 in his family. a Left
MCA territory hypodencities in
brain CT scan (a) and increased
signal of cortex, white matter,
head of left caudete, lentiform
nulclei, and anterior horn of in-
ternal capsule in T2 and FLAIR
brain MRI sequences (c, d), in
favor of subacute infarct. b Small
subpleuroal consodiation in supe-
rior segment of right lung inferior
lobe highly suggestive for
COVID-19
Fig. 2 Thirty-nine-year-old male
with fever, cough, and mylgia
from 6 days before presentation
and sudden onset of left side
hemiplegia and dysartheria. a
Hypodensities in right MCA
branch territorty suggestive of
subacute infarct. b Diffused
ground glass opacities with
interalobular septal thickening in
superior segment of left lung
lower lobes highly suggestive for
COVID-19
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Mean (±standard deviation) of National Institutes of Health
Stroke Scale (NIHSS) for the patient was 10.16 ± 7.13 (ranged
5–24). Detailed clinical features and outcomes of the patients
are noted in Table 1. In addition, the initial laboratory findings
are shown in Table 2.
All patients underwent imaging studies for stroke and also
chest CT scan with low-dose protocol [9]. The initial chest CT
scan evaluated for estimation of lung involvement score using
zonal involvement percentage method with the maximum
score of 24 [10]. The mean score (±SD) was 13.16 ± 6.49
(ranged 2–16) and bilateral ground glass opacities were the
most predominant pattern (Fig. 2).
Brain CT scan findings revealed the stroke territories as
follows: right middle cerebral artery (MCA) infarction (n = 3),
left MCA (n = 2), and left basal ganglia infarction (n = 1), and
the majority of the patients had large vessel stroke. Figures 1, 2,
and 3 show brain CT beside lung CT scans of three patients.
Our data demonstrated that the majority of our patients had low
lung involvement rate while they had more severe conditions
based on NIHSS score. Carotid duplex was negative for any
significant findings (stenosis, atherosclerotic plaque, or dissec-
tion) and results of transcranial color-coded duplex ultrasonog-
raphy (TCCS) have been summarized in Table 3.
Regarding our national guidelines, all patients were placed
on hydroxychloroquine 400 mg stat and lopinavir/ritonavir
400/100 mg twice daily and intravenous antibiotic. In addi-
tion, because all the patients were presented to the emergency
room 3 h after their symptom initiation, they were not candi-
date for thrombolytic therapy so all of them underwent med-
ical treatment with ASA and Plavix for secondary prevention.
All patients were followed up to the study endpoint, five pa-
tients were discharged; however, one case did not survive.
Discussion
This series showed the co-occurrence of stroke and COVID-
19 in adults younger than 55 years of age. To date, there is
limited data on the association of COVID-19 and ischemic
stroke mechanism, clinical course, prevention, management,
and risk stratification.
Valderrama et al. reported a 52-year-old man with COVID-
19 who presented with sudden onset hemiparesis and aphasia
(NIHSS: 20) on his seventh day of treatment and brain CT
scan confirmed the diagnosis of stroke in MCA territory. On
further work up, they did not find any risk factor for stroke
[11].
Fig. 3 Forty-nine-year-old
female with pervious history of
moderate COVID-19 who admit-
ted to our stroke unit with left side
hemiplegia, sensory deficiet, and
dysarthria. a Wedge-shaped
hypodensities in right MCA terri-
tory consistent with subacute in-
farct in brain CT scan. b Diffused
peripheral and central
consoliadtion patches with crazy
paving pattern in some areas
consistent with late phase of
COVID-19
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TCCS transcranial color-coded duplex ultrasonography,MCAmiddle ce-
rebral artery
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In this study, the majority of our patients (five/six) were not
known cases of COVID-19 infection and all of them were
admitted to our stroke unit with neurological complaints while
Mao et al. reported the occurrence of stroke in approximately
2% of COVID-19 patients during their admission [12]. In a
study by TJOxley et al., large-vessel strokes were presented in
five COVID-19 cases younger than 50 years old, and unlike
our patients, all of them had severe COVID-19 [13].
Avula et al., described acute stroke in four old-aged patients
(range 73–88 years) with confirmed diagnosis of COVID-19,
while the oldest patient in this study was 53 years old [14].
It seems that factors such as direct virus invasion, inflam-
matory processes, cytokine release, hypoxemia, hypotension,
or vasculitis are possible mechanisms of coronavirus affecting
the nervous system.
This is the first study evaluating the association of long
involvement extension and stroke severity. In this regard,
our cases showed that lung involvement extension may be
unrelated to developing a stroke and its severity based on
NIHSS. On the other hand, D-Dimer level may play a critical
role as a prognostic factor as elevated D-Dimer levels were
seen in all of our patients.
Poggiali et al. reported two cases of COVID-19 who
complicated with DVT and PE after at least 10 days
since their symptoms started [15]. Also, based on a
recent study, COVID-19 could be predisposed to venous
and arterial thromboembolism leading to diffuse intra-
vascular coagulation, severe inflammation, immobiliza-
tion, and hypoxia [16].
An investigation on ICU-admitted patients with COVID-
19 showed that the incidence of thrombotic complications was
extremely high (31%). The study revealed that pharmacolog-
ical thrombosis prophylaxis is critically important to be added
to the treatment regimen of all COVID-19 patients admitted to
ICU [16].
Conclusion
In conclusion, COVID-19 can cause thrombotic complica-
tions, hyper-inflammation, and tissue damage, which may in-
crease the risk of ischemic stroke in young and middle aged
patients even in early stages and mild forms of COVID-19.
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